🔗 Share this article

As the US continues making unprecedented changes to its vaccine guidelines, one figure has emerged in a surprising turn: Tracy Beth Høeg, a US-based physician and epidemiologist who initially gained attention by expressing skepticism about coronavirus vaccines throughout the pandemic and has zeroed in on possible fatalities after COVID-19 immunization in her short position at the US Food and Drug Administration (FDA).

Planned Changes to Childhood Vaccine Schedule

Public health authorities had intended to reveal radical changes to the pediatric vaccination calendar in December, synchronizing the US with the Danish immunization schedule, sources say – a substantial departure that would put the US out of alignment with many the world with little proof for benefit. The planned update has been postponed until the next year.

Rather than the director of the vaccine center, Høeg is listed to address the audience at the event. She was recently named temporary leader of the FDA’s CDER, the fifth appointee to head the office this calendar year.

Consolidating Power at the FDA

This interim role may indicate a closer partnership between the drug and biologics branches as Høeg and Dr. Prasad solidify control at the FDA – and it points to a greater focus upon dismantling previously authorized immunizations at the FDA.

The new acting director has frequently advocated for ending specific pediatric shot schedules in the US so as to align more similar to Denmark, a country with nationalized medicine and a population approximately the population of the state of Wisconsin.

So far statements, she has kept her attention on vaccines – usually the domain of Prasad, director of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Questions Over Qualifications

The appointee has no apparent experience in pharmaceutical research, regulation or leadership, which has been customary for previous leaders of the biologics center. She has been employed at the FDA as a top consultant to the FDA chief and CBER since March.

“She appears not to have the requisite experience” for running the drug-regulation department, stated Jonathan Howard. “She’s never run a clinical trial. She has no expertise in leading a major agency. She is not an expert in industry regulation.”

Past commissioners of CBER would “be deeply familiar with legal statutes and the research of medication creation”, said Dr. Janet Woodcock. “Frankly, she doesn’t have the kind of background that prior appointees who ran the center have had.”

This division has an immense portfolio at the agency, Woodcock emphasized.

“Everybody just pays attention on the new drug program, but the generic drug division authorizes a multitude of off-brand pharmaceuticals. There’s a biosimilars division, over-the-counter program and other areas, and every single one need to be supervised,” she explained. “The responsibility you neglect, that is the part that I always told people is going to come back to haunt you.”

Additionally, a significant administrative element to the role, which manages more than 5,000 staff members. “It is a enormous leadership role, if you execute it properly,” she concluded.

Response and Disputed Policies

Regarding questions about Dr. Høeg's fitness for the role and whether this appointment signifies greater collaboration among FDA leaders on immunizations, a press secretary responded that the “concerns are based on incorrect assumptions”.

“Her resume is consistent with the functions of her position,” the spokesperson stated, citing the period Høeg spent counseling the agency head on “drug safety and approval science, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Høeg takes over the agency head's new expedited review system, a contentious rapid therapy clearance system that allegedly concerned her preceding directors. “How are these drugs being picked for this fast-track system? Who is making the decisions?” Howard said. “There’s a lot of confidentiality occurring at the agency right now.”

Broadly speaking, he remarked, “the agency appears to be shifting towards less stringent oversight of most medications, except for shots.”

Established History on Immunizations

With vaccines, Dr. Høeg has a more established, if concerning, history, critics observe. She published a analysis using unverified crowd-sourced reports to determine the rate of myocarditis after Covid immunization. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who reportedly have modified findings to indicate Covid vaccinations are more dangerous than they are.

Part of her “wish list” for the incoming administration featured revising rules for novel immunizations and ending “non-essential” immunizations, she said following the vote on a audio program. At the agency, Dr. Høeg has reportedly proposed excluding teenage boys from getting Covid vaccinations.

“She’s an complete ideologue who starts off with her beliefs and works backwards to fit the science in a very disingenuous, fraudulent fashion,” Dr. Howard argued.

Taking Control and a “Revenge Tour”

Dr. Høeg became part of fellow dissenters, {like|